News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
321,202 Results
Type
Article (17328)
Company Profile (107)
Press Release (303767)
Section
Business (109359)
Career Advice (751)
Deals (19306)
Drug Delivery (73)
Drug Development (41150)
Employer Resources (67)
FDA (7080)
Job Trends (7268)
News (180614)
Policy (16259)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (640)
Adcomms (6)
Allergies (32)
Alliances (25831)
ALS (38)
Alzheimer's disease (462)
Antibody-drug conjugate (ADC) (47)
Approvals (7107)
Artificial intelligence (112)
Autoimmune disease (9)
Automation (4)
Bankruptcy (180)
Best Places to Work (5280)
BIOSECURE Act (9)
Biosimilars (54)
Biotechnology (48)
Bladder cancer (21)
Brain cancer (16)
Breast cancer (94)
Cancer (684)
Cardiovascular disease (64)
Career advice (652)
Career pathing (12)
CAR-T (38)
Cell therapy (125)
Cervical cancer (5)
Clinical research (34344)
Collaboration (359)
Compensation (143)
Complete response letters (16)
COVID-19 (946)
CRISPR (19)
C-suite (138)
Cystic fibrosis (49)
Data (677)
Denatured (16)
Depression (11)
Diabetes (106)
Diagnostics (1920)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (18)
Drug discovery (62)
Drug pricing (67)
Drug shortages (15)
Duchenne muscular dystrophy (37)
Earnings (42624)
Editorial (20)
Employer branding (5)
Employer resources (59)
Events (44312)
Executive appointments (438)
FDA (7509)
Featured Employer (21)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Funding (280)
Gene editing (42)
Generative AI (8)
Gene therapy (121)
GLP-1 (373)
Government (1651)
Grass and pollen (2)
Guidances (21)
Healthcare (5804)
Huntington's disease (7)
IgA nephropathy (9)
Immunology and inflammation (37)
Indications (11)
Infectious disease (990)
Inflammatory bowel disease (68)
Inflation Reduction Act (6)
Influenza (15)
Intellectual property (48)
Interviews (94)
IPO (7767)
IRA (31)
Job creations (2222)
Job search strategy (594)
Kidney cancer (7)
Labor market (13)
Layoffs (209)
Leadership (3)
Legal (4048)
Liver cancer (22)
Lung cancer (91)
Lymphoma (54)
Machine learning (1)
Management (20)
Manufacturing (166)
MASH (35)
Medical device (3097)
Medtech (3100)
Mergers & acquisitions (11769)
Metabolic disorders (292)
Multiple sclerosis (22)
NASH (15)
Neurodegenerative disease (28)
Neuropsychiatric disorders (8)
Neuroscience (652)
NextGen: Class of 2025 (2244)
Non-profit (941)
Northern California (861)
Now hiring (9)
Obesity (160)
Opinion (139)
Ovarian cancer (26)
Pain (52)
Pancreatic cancer (17)
Parkinson's disease (51)
Partnered (6)
Patents (109)
Patient recruitment (33)
Peanut (12)
People (36172)
Pharmaceutical (66)
Pharmacy benefit managers (12)
Phase I (9360)
Phase II (14757)
Phase III (12674)
Pipeline (427)
Podcasts (49)
Policy (62)
Postmarket research (1478)
Preclinical (3677)
Press Release (35)
Prostate cancer (47)
Psychedelics (13)
Radiopharmaceuticals (145)
Rare diseases (189)
Real estate (2946)
Recruiting (28)
Regulatory (11448)
Reports (18)
Research institute (750)
Resumes & cover letters (90)
Rett syndrome (1)
RNA editing (1)
RSV (7)
Schizophrenia (39)
Series A (55)
Series B (18)
Service/supplier (4)
Sickle cell disease (34)
Southern California (816)
Special edition (9)
Sponsored (12)
Startups (1901)
State (2)
Stomach cancer (4)
Supply chain (36)
The Weekly (32)
United States (8288)
Vaccines (205)
Venture capitalists (19)
Webinars (10)
Weight loss (113)
Women's health (13)
Worklife (4)
Date
Today (49)
Last 7 days (270)
Last 30 days (1404)
Last 365 days (15596)
2025 (3046)
2024 (15976)
2023 (17948)
2022 (24561)
2021 (25419)
2020 (23939)
2019 (18943)
2018 (14862)
2017 (16484)
2016 (15697)
2015 (18338)
2014 (14695)
2013 (12351)
2012 (13340)
2011 (13882)
2010 (12659)
Location
Africa (366)
Alabama (16)
Alaska (3)
Arizona (75)
Arkansas (4)
Asia (23315)
Australia (3112)
California (2008)
Canada (1037)
China (227)
Colorado (119)
Connecticut (82)
Delaware (57)
Europe (46427)
Florida (335)
Georgia (61)
Idaho (12)
Illinois (199)
India (14)
Indiana (182)
Iowa (1)
Japan (83)
Kansas (57)
Kentucky (13)
Maine (7)
Maryland (357)
Massachusetts (1636)
Michigan (44)
Minnesota (112)
Missouri (27)
Montana (21)
Nebraska (12)
Nevada (15)
New Hampshire (19)
New Jersey (841)
New Mexico (12)
New York (566)
North Carolina (438)
North Dakota (2)
Northern California (861)
Ohio (61)
Oklahoma (7)
Oregon (17)
Pennsylvania (483)
Puerto Rico (5)
Rhode Island (9)
South America (595)
South Carolina (2)
Southern California (816)
Tennessee (38)
Texas (301)
Utah (53)
Virginia (75)
Washington D.C. (33)
Washington State (128)
West Virginia (1)
Wisconsin (12)
321,202 Results for "parnell pharmaceuticals holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering
Parnell Pharmaceuticals Holdings Ltd announced the extension of the backstopped rights offering to raise gross proceeds of approximately US$4.0 million.
January 6, 2023
·
3 min read
Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering
Parnell Pharmaceuticals Holdings Ltd commenced its previously announced backstopped rights offering to raise gross proceeds of approximately US$4.0 million.
December 6, 2022
·
4 min read
Deals
Parnell Pharmaceuticals Holdings Ltd Announces Proposed Rights Offering
Parnell Pharmaceuticals Holdings Ltd (OTC Pink ® Open Market: PARNF) (“Parnell”) announced its intention to raise US$4.0 million through a backstopped rights offering at no charge (the “Rights Offering”) for qualifying shareholders of record as of December 6, 2022 (the “Record Date”).
December 1, 2022
·
3 min read
Press Releases
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
February 21, 2025
·
3 min read
Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum
Parnell Pharmaceuticals Holdings Ltd, a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Friday, 15th July 2022 at 8:30 a.m..
June 21, 2022
·
2 min read
Press Releases
Genflow Biosciences PLC Announces Holding(s) in Company - 2
January 13, 2025
·
2 min read
Press Releases
Genflow Biosciences PLC Announces Holding(s) in Company - 1
January 13, 2025
·
3 min read
Press Releases
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
January 21, 2025
·
6 min read
Press Releases
KRTL Holding Announces KRTL Biotech Facilitates FDA Registration of SIGMACORP as a U.S. Pharmaceutical Manufacturer
December 6, 2024
·
4 min read
BioCapital
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.
June 6, 2024
·
3 min read
1 of 32,121
Next
